RESUMO
BACKGROUND: Lower serum concentrations of the osteoblast-derived protein, osteocalcin, have been associated with poorer glycemic control, insulin resistance and atherosclerosis, and with the development of type 2 diabetes (T2DM). METHODS: This study compares concentrations of two physiological forms of osteocalcin, carboxylated (cOCN) and uncarboxylated (unOCN), between participants with T2DM (nâ¯=â¯20) and age-, gender- and body mass index (BMI)-matched participants without T2DM (nâ¯=â¯40) among patients with coronary artery disease (CAD), and it explores relationships between osteocalcin concentrations and cardiovascular risk factors. RESULTS: Concentrations of unOCN (2.71⯱â¯1.86 vs. 4.70⯱â¯2.03â¯ng/mL; tâ¯=â¯-3.635, pâ¯=â¯0.001) and cOCN (8.70⯱â¯2.27 vs. 10.77⯱â¯3.69â¯ng/mL; tâ¯=â¯-2.30, pâ¯=â¯0.025) were lower in participants with T2DM. In participants without T2DM, concentrations of cOCN were associated with fitness (VO2Peak rhoâ¯=â¯0.317, pâ¯=â¯0.047) and lower body fat (rhoâ¯=â¯-0.324, pâ¯=â¯0.041). In participants with T2DM, lower unOCN was associated with HbA1c (rhoâ¯=â¯-0.516, pâ¯=â¯0.020). Higher body mass was associated with higher unOCN (rhoâ¯=â¯0.423, pâ¯=â¯0.009) in participants without T2DM, but with lower concentrations of both unOCN (rhoâ¯=â¯-0.590, pâ¯=â¯0.006) and cOCN (rhoâ¯=â¯-0.632, pâ¯=â¯0.003) in participants with T2DM. CONCLUSION: In patients with CAD, lower osteocalcin concentrations were related to type 2 diabetes, and to adverse fitness, metabolic and obesity profiles.